InflaRx (IFRX) Common Equity (2016 - 2026)

InflaRx has disclosed Common Equity across 11 years of filings, most recently posting $8.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $8.4 million, up 9.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (up 9.26% YoY), and the FY2025 annual result was $8.3 million, up 4.99% from the prior year.
• Common Equity came in at $8.4 million for Q1 2026 at InflaRx, roughly flat from $8.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $110.4 million in Q4 2023 to a low of $4.9 million in Q1 2022.
• The 5-year median for Common Equity is $8.0 million (2024), against an average of $19.1 million.
• Across the five-year window, Common Equity surged 1926.68% in 2022 and plunged 92.8% in 2024, its largest moves.
• InflaRx's Common Equity stood at $90.1 million in 2022, then increased by 22.45% to $110.4 million in 2023, then sank by 92.8% to $8.0 million in 2024, then rose by 4.99% to $8.3 million in 2025, then grew by 0.37% to $8.4 million in 2026.
• The last three Common Equity figures came in at $8.4 million (Q1 2026), $8.3 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.